Gray market peptides outpace the human evidence behind them

Injectable compounds sold with a research use only label have moved from bodybuilding forums into wellness spas, social media feeds and ordinary shops, a WHYY report described on 19 October. Gray market peptides are now widely used for injuries, recovery and weight loss. The human evidence behind most of them is thin, regulators treat them as unapproved drugs, and nobody checks what is in the vial.

What the label does not mean

Vials in this trade usually carry the words research use only, which suggests laboratory work rather than human use. The phrase has no force in American drug law. In a warning letter to one seller, the FDA wrote that despite such statements on the labeling, evidence from the company's own website showed the products were intended as drugs for human use, which makes them unapproved new drugs under the Federal Food Drug and Cosmetic Act. The agency pointed to claims about appetite, insulin sensitivity and body weight on product pages, and to the sale of injection water next to powders that must be dissolved, as evidence of that intent.

Enforcement has picked up through 2026. Letters went to peptide sellers in March, in June and again in late August, several of them naming compounds that copy approved or investigational medicines. The letters also make the agency's safety reasoning explicit: injected products go straight into the body and bypass defences against toxins and microorganisms, so contamination carries more risk than it would in a pill. A letter is not a court order. It asks the company to respond within fifteen working days and warns that seizure or an injunction may follow. Sites close, and others open. The practical result is that enforcement shapes who sells these products rather than whether they are sold, and buyers see the same vials under new names.

What the research on BPC 157 actually shows

The compound at the centre of this market is BPC 157, a short peptide first isolated from human gastric juice in 1993. A scoping review from the University of Utah, published in Current Reviews in Musculoskeletal Medicine in August 2025, searched six databases through March 2025 and found a large animal literature: healing of tendon, muscle, nerve and bone injuries in rodents, with mechanisms running through blood vessel growth, nitric oxide signalling and fibroblast activity. The review describes that preclinical record as robust. It then reports that human data are extremely limited, with only three pilot studies, covering knee pain injected into the joint, interstitial cystitis and an intravenous safety study.

A large animal literature stands behind BPC 157 while the human record rests on three small pilot studies, none of them large or long.

A large animal literature stands behind BPC 157 while the human record rests on three small pilot studies, none of them large or long. No adverse effects were reported in them, and the authors conclude that BPC 157 should be treated as investigational until well designed trials exist. That gap between animals and people is the normal state of early research, not a scandal. It is also exactly what the selling of gray market peptides skips over. The regulatory position reflects the same gap. The World Anti Doping Agency banned BPC 157 in 2022 under its S0 category for unapproved substances, and in September 2023 the FDA classified it as a Category 2 bulk drug substance, which keeps it out of compounded medicines.

Why gray market peptides carry extra uncertainty

Even when a compound has promise, a vial bought outside the regulated system is an unknown quantity. There is no release testing a buyer can see, no assurance of identity, purity or sterility, and no recall route if something is wrong. WHYY reported two episodes that show how hard the harms are to pin down. Two women were hospitalised in critical condition, needing ventilators, after injections at a Las Vegas festival last year; both recovered, and investigators could not test the substances involved, so the cause stayed unknown. CBS News later reported that the FDA had received reports of two deaths involving products claimed to contain retatrutide, an unapproved compound in development, with the reports unverified and the role of the products unclear.

Unverified reports are the usual form this evidence takes. Adverse event systems depend on someone filing a report, laboratories rarely receive the actual material, and a person taking several compounds at once makes attribution harder still. A case series cannot separate a reaction to the compound from a reaction to a contaminant or to the injection itself. The same difficulty appears in online self reports. Our coverage of a language model that read Reddit reports on gray market retatrutide found increased appetite near the top of the symptom list, the opposite of what trials of the drug describe, and nobody could confirm what the posters had taken.

What would close the gap

Clinicians quoted by WHYY say patients now ask about these compounds constantly, and attribute the shift partly to falling trust in medical institutions and partly to the success of approved peptide drugs such as the GLP 1 medicines studied in large datasets. Both explanations are the clinicians own reading of why their clinics changed, not a measured finding, and neither has been tested. Insulin and the GLP 1 drugs show what the regulated path produces: trials, labels, known side effects and a manufacturer who can be held responsible. The contrast is not between peptides that work and peptides that do not. It is between compounds that have been tested in people and compounds that have not.

Closing that gap takes trials, and trials need funding that a cheap unpatentable peptide rarely attracts. The authors call directly for well designed human studies of BPC 157, given the preclinical evidence and the level of public interest. Useful studies would have control groups, defined products assayed before use, and tracking over months rather than a question asked long after the fact. Registry work could also help by recording what people actually take and what happens to them. Until that exists, anyone weighing gray market peptides is reasoning from rodents, and from a vial whose contents nobody has checked. The FDA warning letter sets out the legal position. The Utah review sets out the evidence and the research it says is missing.

Conclusion

The market in gray market peptides has grown far faster than the research behind it. For BPC 157, the best studied of them, there is a large animal literature and three small human pilot studies, which is not enough to judge benefit or long term risk. Regulators treat these products as unapproved drugs, harms are reported but rarely verified, and the vials themselves are untested.

Source Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med (2025). DOI 10.1007/s12178-025-09990-7; FDA warning letters to peptide sellers, 2026; WHYY The Pulse report, 19 October 2026

Amino Weekly reports research. It is not medical advice and never gives doses.